Bruce Perkins - Amedisys Independent Director
| AMED Stock | USD 91.84 0.05 0.05% |
Director
Mr. Bruce D. Perkins is Independent Director of the Amedisys, Inc. Mr. Perkins, the managing member for Perkins, Smith, Associates, L.L.C., based in Louisville, Kentucky, serves on the boards of three private healthcare companies. Mr. Perkins serves as a strategic executive for Baroma Midco, L.L.C. a strategic advisor and executive coach for ChenMed, a Florida based MSO a senior advisor for the Marwood Group a senior advisor for US Imaging and a consultant for Conviva, Interpreta, Devoted Health and Heath Care Service Corporationrationration. He also serves on the Advisory Board of the University of Louisville College of Business. He previously served as chairman of the board of MCCI Group Holdings, a board member of Humana Health Plan of Puerto Rico, a strategic advisor for MCCI Group Holdings, and the treasurer of the American Association of PPOs . Mr. Perkins retired from Humana, Inc. at the end of 2014 after a thirtyeight year career, most recently as President of Humanas Healthcare Services Segment, which included the companys pharmacy business, home care business, behavioral health business, physician businesses, and all clinical and provider network functions. Prior to his role as President of Healthcare Services, Mr. Perkins served as Regional Vice President and Divisional President for Humana health plans across multiple markets, and prior to the spinoff Humanas hospital business, Mr. Perkins held multiple leadership positions including Divisional Vice President and hospital CEO, COO, and CFO. since 2015.
| Age | 64 |
| Tenure | 9 years |
| Address | 3854 American Way, Baton Rouge, LA, United States, 70816 |
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0626 % which means that it generated a profit of $0.0626 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0187) %, meaning that it created substantial loss on money invested by shareholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.13, whereas Return On Tangible Assets are projected to grow to (0.01). At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 24 M, whereas Intangible Assets are forecasted to decline to about 64.1 M.Similar Executives
| Found 13 records | DIRECTOR Age | ||
| David Nash | Humana Inc | 62 | |
| William Mitchell | Humana Inc | 73 | |
| Roy Dunbar | Humana Inc | 56 | |
| Karen Katz | Humana Inc | 64 | |
| Marissa Peterson | Humana Inc | 58 | |
| William McDonald | Humana Inc | 64 | |
| David Jones | Humana Inc | 71 | |
| David Feinberg | Humana Inc | 58 | |
| Frank Bisignano | Humana Inc | 62 | |
| Karen DeSalvo | Humana Inc | 52 | |
| James Brien | Humana Inc | 62 | |
| Frank DAmelio | Humana Inc | 63 | |
| James OBrien | Humana Inc | 66 | |
Management Performance
| Return On Equity | -0.0187 | ||||
| Return On Asset | 0.0626 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Mccoy, COO | ||
| Christopher Gerard, COO | ||
| Michael North, Senior Vice President - Operations | ||
| Larry Pernosky, Chief Human Resource Officer | ||
| Janet Britt, VP Collections | ||
| Richard Ashworth, CEO President | ||
| Scott Ginn, Chief Accounting Officer | ||
| Jeffrey Rideout, Director | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| David Kemmerly, Senior Vice President - Government Affairs | ||
| Lawrence Pernosky, Chief Human Resource Officer | ||
| Nathaniel Zilkha, Director | ||
| Adam Holton, Chief Officer | ||
| Bruce Perkins, Independent Director | ||
| Susan Sender, Chief Clinical Operations Officer | ||
| Stephen Seim, Chief Strategy Officer | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Donald Washburn, Non-Executive Co-Chairman of the Board | ||
| Jeffrey Jeter, Chief Compliance Officer | ||
| Martin Howard, CIO | ||
| Jennifer Griffin, Deputy VP | ||
| Jane Carmody, Chief Clinical Operations Officer | ||
| Sharon Brunecz, Chief Human Resource Officer | ||
| Ronald LaBorde, Vice Chairman and CFO | ||
| Allyson Guidroz, Chief Officer | ||
| Linda Hall, Independent Director | ||
| Julie Klapstein, Director | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| David Pearce, Chief Compliance Officer | ||
| Jake Netterville, Independent Director | ||
| Dan McCoy, COO | ||
| Gary Willis, CFO | ||
| Richard Lechleiter, Director | ||
| David Castille, IR Contact Officer, Director, Treasury/Finance |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0187 | ||||
| Return On Asset | 0.0626 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 3.43 B | ||||
| Shares Outstanding | 32.68 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 94.99 % | ||||
| Number Of Shares Shorted | 2.39 M | ||||
| Price To Earning | 15.03 X |
Pair Trading with Amedisys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.Moving together with Amedisys Stock
| 0.8 | TFX | Teleflex Incorporated Earnings Call This Week | PairCorr |
| 0.81 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
Moving against Amedisys Stock
| 0.66 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.56 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share (0.64) | Revenue Per Share 69.004 | Quarterly Revenue Growth 0.027 | Return On Assets 0.0626 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.